Federal Government Engagements
Federal Government Advocacy
Federal legislation, regulatory action, and agency decisions shape many of the issues that matter most to our families. From research funding and Medicaid access to disability rights and drug development standards. While many organizations advocate broadly, families living with Developmental and Epileptic Encephalopathies (DEEs) and Severe Neurological Impairments (SNIs) face distinct and urgent needs that are too often overlooked.
DEEP works to ensure policymakers hear directly from the families living this reality, and that the urgency of our community's needs is visible in the decisions that affect them.
How We Engage
Some of DEEP's advocacy happens on behalf of the community: through Hill days, formal comment letters, and leadership roles in national epilepsy initiatives.
Other opportunities are ones you can join directly, whether that's contacting your elected officials, responding to a public comment period, or sharing your family's story.
Save the Date: April 9, 2027
DEEP EL-PFDD: DEE Voices for Drug Development
DEEP is hosting an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting focused on Developmental and Epileptic Encephalopathies (DEEs).
This meeting brings caregivers directly to the table with the FDA, giving families a formal voice in how new treatments are developed and evaluated.
Agenda and speaker details are still being finalized.

Our Approach to Federal Government Engagement
Our advocacy combines scientific evidence with the lived experiences of the DEE community. This approach helps ensure our recommendations are both community-driven and grounded in evidence.
Our Advocacy Efforts
See DEEP's federal engagement track record, from comment submissions to Hill Days
Federal Agencies We Engage With
Learn who these agencies are and why they matter to our community
Take Action
Review our 5 minute Advocacy Menu!
Our Advocacy Efforts
DEEP's federal engagement, in action.
DEEP's advocacy combines scientific evidence with the lived experience of the DEE/NDD community. Below is a record of our formal engagement with federal agencies and initiatives. Comment submissions, convenings, and collaborative sessions that bring family voices directly into decisions that affect them.
United States Food and Drug Administration (FDA)
DEEP Patient Listening Session (November 2024)
DEEP, in partnership with the Rare Epilepsy Network (REN), brought caregivers directly to the table with FDA reviewers to share what daily life with a DEE or an SNI really looks like. Seven families spoke to what matters most for future treatments, and DEEP's summary urged the FDA to:
- Recognize the challenges shared across DEE diagnoses — uncontrolled seizures, communication barriers, and disrupted sleep — regardless of the specific genetic cause
- Reduce barriers to clinical trial participation, including financial strain, travel burden, and narrow eligibility criteria that exclude many families
- Adopt outcome measures that capture small but meaningful gains — like improved eye contact, communication, or muscle tone — that standard clinical scales often miss
- Weigh families' willingness to accept real risk in exchange for treatments that could meaningfully improve day-to-day quality of life
DEEP Critical Path Innovation Meeting (CPIM) (April 2025, with Inchstone)
CPIM sessions are structured, off-the-record forums that facilitate dialogue between the FDA and external stakeholders on emerging scientific questions in drug development. In April 2025, the Inchstone team used this opportunity to present their accomplishments and share their strategic vision moving forward. Our CPIM, Fit-for-purpose assessment for individuals with severe to profound developmental impairments, brought together key leaders in the DEE space, including caregivers, patient advocacy leaders, leading clinicians and researchers, and pharmaceutical partners.
A key focus was Inchstone's work on measuring and tracking communication in populations more profoundly impacted by disease: an area where they both showcased progress and sought critical feedback from FDA stakeholders to refine their approach.
This engagement is one more step toward DEEP's upcoming Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting, where caregivers will have a formal, public voice directly with the FDA.
Learn more about the CPIM process here

Plausible Mechanism Framework
The FDA opened a comment period to gather input as it developed a new framework for evaluating treatments for rare diseases. DEEP's recommendations urged the FDA to:
- Accept natural history studies and real-world patient data as evidence
- Include and compensate patients and caregivers throughout the process
- Make the framework flexible for ultra-rare diseases where traditional trials aren't possible
- Clearly explain what evidence drug developers need to provide
U.S. Access Board
Universal Changing Stations
The U.S. Access Board proposed new accessibility standards for universal changing stations in airports. DEEP's recommendations urged that the standards:
- Ensure changing stations are large, safe, and usable for people of all ages and body sizes
- Include features like powered height-adjustable tables and higher weight capacities
- Reflect real caregiver experiences in the final standards
Office of Management and Budget (OMB)
Federal Financial Assistance
The federal government opened this comment period to propose changes to the rules governing how federal grants are awarded and managed. It sought feedback from organizations that receive or rely on federal funding before finalizing the rule.
Our recommendations were meant to:
- Protect fair and transparent grant review.
- Reduce unnecessary administrative burdens.
- Ensure patient organizations can continue to participate in federally funded research and programs.
- Keep funding decisions focused on scientific merit and public benefit.
Learn More About The Federal Decision Makers We Engage With
Understanding who shapes the policies that affect our community.
Congress
Congress, made up of the House of Representatives and the Senate, writes and passes the laws that determine research funding, healthcare access, and protections for people with disabilities. DEEP engages with Congress through Hill Days, coalitions like the National Epilepsy Caucus, and support for legislation such as the National Plan for Epilepsy, helping ensure lawmakers hear directly from the families affected by their decisions.
U.S. Food and Drug Administration (FDA)
The FDA decides how new treatments are evaluated and approved, including what evidence is required and how patient experience factors into that process. DEEP engages with the FDA through public comment periods, Patient-Focused Drug Development meetings, and formal partnerships like our upcoming EL-PFDD, ensuring the realities of DEE/NDD families directly inform how new treatments are developed and reviewed.
U.S. Access Board
The U.S. Access Board sets accessibility standards for the spaces and equipment people with disabilities rely on every day, from public buildings to changing tables in airports. DEEP engages with the Access Board through public comment periods, including our recommendations on universal changing station standards, ensuring the needs of medically complex children and their caregivers are reflected in the guidelines that get adopted.
Office of Management and Budget (OMB)
OMB oversees the rules that govern how federal funding and research grants are awarded and managed across government agencies. DEEP engages with OMB through public comment periods on proposed rule changes, helping protect fair and transparent grantmaking and ensuring patient organizations can continue to participate in federally funded research.
Featured Federal Advocacy Resources
Take Action Now
Our 5 Minute Advocacy Menu
Looking to make an impact with limited time to spare? Advocate with ease by selecting one of the following options and messaging your elected officials on important issues in the epilepsy community. We will update this section with active advocacy campaigns
